ImmunityBio, Inc.
IBRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001326110
In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 406 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.
Holders of 5% or more of IBRX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of ImmunityBio, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Cambridge Equities, LP | 13D/A | 64.80%745.5M shares | −1.50 ppfrom 66.30% | Mar 12, 20218 filings | Aug 6, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
8 Schedule 13D and 13G filings on ImmunityBio, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 20266:50 PM ET | Cambridge Equities, LPand 5 others | 13D/A | 64.80%745.5M shares | −1.50 ppfrom 66.30% | Jul 31, 2026 | SEC |
| Feb 25, 20269:51 PM ET | Cambridge Equities, LPand 5 others | 13D/A | 66.30%745.6M shares | −2.60 ppfrom 68.90% | Feb 23, 2026 | SEC |
| Nov 10, 20257:43 PM ET | Cambridge Equities, LPand 6 others | 13D/A | 68.90%744.0M shares | – | Nov 10, 2025 | SEC |
| Jan 4, 2024 | Cambridge Equities, LP | 13D/AOld format | – | – | – | SEC |
| Sep 21, 2023 | Cambridge Equities, LP | 13D/AOld format | – | – | – | SEC |
| May 23, 2023 | Cambridge Equities, LP | 13D/AOld format | – | – | – | SEC |
| Dec 7, 2022 | Cambridge Equities, LP | 13D/AOld format | – | – | – | SEC |
| Mar 12, 2021 | Cambridge Equities, LP | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
11 notices from officers, directors and other affiliates planning to sell ImmunityBio, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Oct 5, 202610:21 AM ET | Simon Barry J.Officer · Director | 560.0K | $7.66M | Oct 5, 202610b5-1 | THE CHARLES SCHWAB CORPORATION | SEC |
| Oct 2, 20264:26 PM ET | Cheryl CohenDirector | 81.1K | $752.2K | Oct 2, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jul 2, 20264:31 PM ET | Cheryl L CohenOfficer | 131.2K | $1.21M | Jul 2, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jul 1, 20264:29 PM ET | Christobel SeleckyDirector | 159.5K | $1.40M | Jul 1, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jun 30, 20264:35 PM ET | Christobel SeleckyDirector | 1.00K | $8.77K | Jun 30, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jun 29, 20264:44 PM ET | Christobel SeleckyDirector | 95.7K | $833.7K | Jun 29, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jun 4, 202611:02 AM ET | Simon Barry J.Officer · Director | 268.0K | $2.95M | Jun 4, 202610b5-1 | THE CHARLES SCHWAB CORPORATION | SEC |
| Feb 23, 20264:28 PM ET | Christobel SeleckyDirector | 25.0K | $217.5K | Feb 23, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jan 20, 20264:29 PM ET | Christobel SeleckyDirector | 25.0K | $138.0K | Jan 20, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jan 20, 202611:05 AM ET | Simon Barry J.Officer · Director | 572.0K | $5.91M | Jan 20, 202610b5-1 | THE CHARLES SCHWAB CORPORATION | SEC |
| Jan 16, 20264:22 PM ET | Christobel SeleckyDirector | 50.0K | $197.5K | Jan 16, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |